Endocrine Abstracts

Background: In January 2018, the 8th edition of the AJCC/TNM staging system for differentiated thyroid cancer (DTC) was introduced in clinical practice. Studies evaluating this 8th edition so far only comprised patients with papillary thyroid cancer (PTC) or made no distinction between PTC and follicular thyroid cancer (FTC). Therefore, we evaluated the prognostic value of the AJCC/TNM 8th edition in a European population with DTC, and subsequently distinguished PTC and FTC pa...

BackgroundThe 2015 American Thyroid Association (ATA) Risk Stratification System for differentiated thyroid cancer (DTC) is designed to predict response to therapy and recurring disease. Although age is not incorporated as a risk factor, recent research suggests that the addition of age can improve this system. However, these studies comprised low number of patients with ATA High Risk, low numbers of patients with follicular thyroid cancer (FTC), and did...

Introduction: Historically, treatment of follicular thyroid carcinoma (FTC) and oncocytic thyroid carcinoma (OTC) is based on thyroidectomy followed by radioiodine (RAI) therapy. Both tumor types have a good prognosis (10-year survival 80-94%), but this changes significantly once RAI-refractory disease occurs (median 3.5 years), which limits further treatment possibilities. The main risk factors for developing RAI-refractory disease in FTC and OTC are unknown. Our aim was to i...

Aim: To evaluate the effectiveness of Peptide Receptor Radionuclide Therapy with 177Lu-octreotate (PRRT) for medullary thyroid carcinoma (MTC).Background: There are few therapeutic options for progressive metastatic MTC. The Erasmus MC Center for Neuroendocrine Tumors has been at the forefront of developing PRRT for neuroendocrine tumors. PRRT has also been suggested to be a useful treatment for MTC, but evidence is very limited.<p class="...